GlassScriptPhysician profile
Chi Jane Ellison
NPI 1376982876
$3,794.10
in general payments reported to CMS, 2019-2025
25 companies · $959 in 2025
The $959 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $277 · 2021: $83.63 · 2022: $498 · 2023: $1,210 · 2024: $652 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,749 · Education: $72.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.14 |
| Education | $72.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $846.14 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $658.32 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.73 | 2020-2023 | Ofev |
| Mallinckrodt Hospital Products INC. | $295.00 | 2022-2025 | Acthar |
| United Therapeutics Corporation | $200.56 | 2023 | Tyvaso |
| Viatris Specialty LLC | $189.68 | 2025 | Yupelri |
| Mylan Specialty L.P. | $165.07 | 2023-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $146.80 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $120.66 | 2021-2025 | Glassia |
| Amgen INC. | $119.71 | 2022-2025 | Tezspire |
| Genentech USA, INC. | $99.99 | 2019 | |
| Grifols USA, LLC | $87.80 | 2023 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $82.47 | 2024-2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $73.32 | 2025 | Ohtuvayre |
| Insmed, INC. | $69.49 | 2023-2025 | Arikayce, Brinsupri |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.83 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Genzyme Corporation | $47.13 | 2024-2025 | |
| Electromed, INC. | $43.25 | 2023-2024 | Smartvest |
| Philips North America LLC | $38.98 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $32.74 | 2023-2024 | |
| La Jolla Pharmaceutical Company | $28.94 | 2020 | |
| Abbvie INC. | $28.26 | 2023 | |
| Pulmonx Corporation | $15.40 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Alexion Pharmaceuticals, INC. | $13.11 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chi Jane Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.